ATE511500T1 - Sulfonamide als orexin-antagonisten - Google Patents
Sulfonamide als orexin-antagonistenInfo
- Publication number
- ATE511500T1 ATE511500T1 AT09703156T AT09703156T ATE511500T1 AT E511500 T1 ATE511500 T1 AT E511500T1 AT 09703156 T AT09703156 T AT 09703156T AT 09703156 T AT09703156 T AT 09703156T AT E511500 T1 ATE511500 T1 AT E511500T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonamides
- orexin antagonists
- orexin
- antagonists
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08150435 | 2008-01-21 | ||
| PCT/EP2009/050272 WO2009092642A1 (en) | 2008-01-21 | 2009-01-12 | Sulfonamides as orexin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE511500T1 true ATE511500T1 (de) | 2011-06-15 |
Family
ID=40551459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09703156T ATE511500T1 (de) | 2008-01-21 | 2009-01-12 | Sulfonamide als orexin-antagonisten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7932269B2 (de) |
| EP (1) | EP2245006B1 (de) |
| JP (1) | JP5220870B2 (de) |
| KR (1) | KR101178658B1 (de) |
| CN (1) | CN101918359B (de) |
| AT (1) | ATE511500T1 (de) |
| AU (1) | AU2009207750B2 (de) |
| BR (1) | BRPI0906522A2 (de) |
| CA (1) | CA2709050C (de) |
| ES (1) | ES2364806T3 (de) |
| IL (1) | IL206359A (de) |
| WO (1) | WO2009092642A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2962649B1 (fr) | 2010-07-19 | 2025-10-24 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| ES2672732T3 (es) | 2012-02-07 | 2018-06-15 | Eolas Therapeutics Inc. | Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina |
| PE20161064A1 (es) * | 2013-12-12 | 2016-10-28 | Univ Tsukuba | Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo |
| JP6663909B2 (ja) | 2014-08-13 | 2020-03-13 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン |
| WO2016133160A1 (ja) * | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| WO2016199906A1 (ja) * | 2015-06-12 | 2016-12-15 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| MX2018009656A (es) | 2016-02-12 | 2019-02-20 | Astrazeneca Ab | Piperidinas halo-sustituidas como moduladores de los receptores de orexinas. |
| US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| JP7012703B2 (ja) * | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| WO2019027003A1 (ja) * | 2017-08-03 | 2019-02-07 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1335901B1 (de) * | 2000-10-17 | 2010-04-14 | Merck Serono SA | Pharmazeutisch aktive sulfonamid-derivate |
| US7279578B2 (en) * | 2002-10-11 | 2007-10-09 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic acid derivatives |
| FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| JP2009503106A (ja) * | 2005-08-04 | 2009-01-29 | メルク エンド カムパニー インコーポレーテッド | アミノエタンスルホンアミドオレキシン受容体アンタゴニスト |
| CA2646917A1 (en) * | 2006-04-11 | 2007-10-18 | Actelion Pharmaceuticals Ltd | Novel sulfonamide compounds |
-
2009
- 2009-01-12 AT AT09703156T patent/ATE511500T1/de active
- 2009-01-12 JP JP2010543459A patent/JP5220870B2/ja not_active Expired - Fee Related
- 2009-01-12 CN CN2009801026222A patent/CN101918359B/zh not_active Expired - Fee Related
- 2009-01-12 CA CA2709050A patent/CA2709050C/en not_active Expired - Fee Related
- 2009-01-12 EP EP09703156A patent/EP2245006B1/de active Active
- 2009-01-12 BR BRPI0906522-9A patent/BRPI0906522A2/pt not_active Application Discontinuation
- 2009-01-12 ES ES09703156T patent/ES2364806T3/es active Active
- 2009-01-12 AU AU2009207750A patent/AU2009207750B2/en not_active Ceased
- 2009-01-12 WO PCT/EP2009/050272 patent/WO2009092642A1/en not_active Ceased
- 2009-01-12 KR KR1020107016193A patent/KR101178658B1/ko not_active Expired - Fee Related
- 2009-01-14 US US12/353,506 patent/US7932269B2/en not_active Expired - Fee Related
-
2010
- 2010-06-14 IL IL206359A patent/IL206359A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186920A1 (en) | 2009-07-23 |
| AU2009207750B2 (en) | 2013-03-14 |
| CA2709050A1 (en) | 2009-07-30 |
| CN101918359A (zh) | 2010-12-15 |
| CN101918359B (zh) | 2013-02-27 |
| AU2009207750A1 (en) | 2009-07-30 |
| IL206359A (en) | 2014-06-30 |
| KR101178658B1 (ko) | 2012-08-30 |
| KR20100092979A (ko) | 2010-08-23 |
| WO2009092642A1 (en) | 2009-07-30 |
| ES2364806T3 (es) | 2011-09-14 |
| JP5220870B2 (ja) | 2013-06-26 |
| EP2245006B1 (de) | 2011-06-01 |
| US7932269B2 (en) | 2011-04-26 |
| EP2245006A1 (de) | 2010-11-03 |
| IL206359A0 (en) | 2010-12-30 |
| CA2709050C (en) | 2016-06-14 |
| JP2011510037A (ja) | 2011-03-31 |
| BRPI0906522A2 (pt) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE511500T1 (de) | Sulfonamide als orexin-antagonisten | |
| ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
| CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
| ATE496051T1 (de) | Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten | |
| EA200870409A1 (ru) | Антагонисты киназы pi3 | |
| CY1119218T1 (el) | Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp) | |
| ATE557019T1 (de) | Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201390877A1 (ru) | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| EA201270149A1 (ru) | Ингибиторы bace | |
| DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
| EA201171293A1 (ru) | 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина | |
| EP2348846A4 (de) | Disubstituierte azepanorexin-rezeptorantagonisten | |
| UA112428C2 (uk) | Пестицидні композиції і пов'язані з ними способи | |
| EA200900635A1 (ru) | Антагонисты прогестеронового рецептора | |
| NO20084007L (no) | Spirokondenserte piperidiner som modulatorer av muskarinreseptorer | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| EA201171211A1 (ru) | Производные оксадиазола | |
| CO6382123A2 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| EP1861399A4 (de) | Cgrp-rezeptorantagonisten | |
| EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
| NO20080265L (no) | 2-(1H-indolylsulfanyl)-arylaminderivater | |
| EA201170585A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
| EA201001882A1 (ru) | Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2245006 Country of ref document: EP |